Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | C203 - Frontotemporal Dementia

Thursday 04/18/24
01:00 PM - 03:00 PM MDT Add To Calendar
Colorado Convention Center | 702/704/706
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Bradley F. Boeve, MD, FAAN
Aging, Dementia, and Behavioral Neurology
Participants should become familiar with the key clinical, genetic, neuropsychological, and neuroimaging aspects of frontotemporal dementia, as well as the current and future management/treatment considerations for those with frontotemporal dementia.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider
Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:30 PM MDT Speaker Clinical, Neuropsychological, and Genetic Aspects of FTD
Bradley F. Boeve, MD, FAAN
01:30 PM - 02:00 PM MDT Speaker Neuroimaging Aspects of FTD
Howard J. Rosen, MD
02:00 PM - 02:30 PM MDT Speaker Management/Treatment Aspects of FTD
Peter A. Ljubenkov, MD
02:30 PM - 03:00 PM MDT Speaker Open Discussion
Bradley F. Boeve, MD, FAAN, Peter A. Ljubenkov, MD, Howard J. Rosen, MD
Faculty Disclosures
Bradley F. Boeve, MD, FAAN Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Howard J. Rosen, MD Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Peter A. Ljubenkov, MD Dr. Ljubenkov has nothing to disclose.